- Allogene reports patient death tied to its CAR-T drug
Allogene Therapeutics said that one of its patients in a clinical trial for its multiple myeloma CAR-T drug died of fungal pneumonia. - Patient death tied to CRISPR Therapeutics’ CAR-T therapy
An off-the-shelf CAR-T cell therapy being developed by CRISPR Therapeutics saw positive results in some patients with advanced B-cell lymphoma, but was also tied to a patient’s death. - FDA halts California drugmaker’s CAR-T trial after patient death
The FDA halted San Diego-based drugmaker Poseida Therapeutics’ clinical trial of a CAR-T therapy after a patient died. - FDA puts clinical hold on Cellectis CAR-T trial after patient dies of cardiac arrest
The FDA put a clinical hold on French drugmaker Cellectis’ trial for its off-the-shelf CAR-T therapy after a patient died of cardiac arrest.
More articles on pharmacy:
Biden team to meet with COVID-19 vaccine-makers this week
HHS partners with 19 pharmacy networks for COVID-19 vaccine allocation
‘Puzzle without the edge and corner pieces’: 2 experts weigh in on Pfizer, Moderna vaccine trial news
